Anteris Technologies Global Corp. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
AVR Nasdaq 3850 anteristech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anteris Technologies Global Corp.

Anteris Technologies appoints Brent Moen as chief financial officer - Sep 6th, 2026 5:47 pm
Anteris to Present at September Healthcare Investor Conferences - Aug 31st, 2026 12:45 pm
Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway - Aug 11th, 2026 5:22 pm
Anteris Technologies Announces Results for the Second Quarter of 2026 - Aug 11th, 2026 5:00 pm
TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge - Jun 15th, 2026 6:05 am
France clearance marks key milestone for Anteris' pivotal PARADIGM Trial - Jun 8th, 2026 5:22 pm
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance - Jun 8th, 2026 4:00 am
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation - May 13th, 2026 2:00 pm
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - May 13th, 2026 6:39 am
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy - May 12th, 2026 7:33 pm
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push - May 12th, 2026 5:43 pm
Anteris Announces Results for the First Quarter of 2026 - May 12th, 2026 5:00 pm
Anteris treats first US patients in DurAVR pivotal trial - May 6th, 2026 7:45 pm
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances - May 6th, 2026 7:45 pm
Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valve - May 6th, 2026 11:40 am
Small Cap Watch: Small Ordinaries edges higher as company news flow continues - May 5th, 2026 6:11 pm
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - May 5th, 2026 4:00 am
Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market Strategy - Mar 12th, 2026 6:35 am